Close menu

July 27th, 2021 | 13:01 CEST

BioNTech, XPhyto Therapeutics, MorphoSys - Here we go again

  • Biotechnology
Photo credits:

The numbers of new SARS-CoV-2 infections in Germany are rising again, albeit still at a relatively low level. Due to the spread of the Delta variant, Health Minister Jens Spahn warns of incidences beyond the 800 mark as early as this fall. In addition to masking and spacing, the issues surrounding vaccines against the various mutations and regular, reliable testing are returning to the front pages of the news pages.

time to read: 3 minutes | Author: Stefan Feulner

Table of contents:

    XPhyto - Enormous pace

    Last year, after the initial lockdown, people were still hoping for a quick end to the pandemic and a return to a free life as they knew it before Corona. Now, more than a year later, it should be clear to everyone that we have to live with the virus, in whatever variant it currently prevails. The profiteers, as morbid as it may sound, are not only the vaccine producers but also the developers of rapid tests and diagnostics. According to one study, the global market for rapid tests is expected to grow by around 9% annually to a total volume of almost USD 40 billion by 2023.

    Well-positioned in this highly competitive market is life science accelerator XPhyto, whose focus is on investing in next-generation drug delivery, diagnostics, and new active pharmaceutical ingredients. In terms of Covid testing, in collaboration with a German partner, sales of the Covid-19 RT-PCR test system "Covid-ID Lab" began in Germany at the end of May. The advantage of the test offered is that Covid-ID Lab requires only a 20-minute PCR run time without prior RNA extraction as part of sample preparation. The product is intended to bridge the gap between single-use antigen tests and centralized, automated PCR systems. Target customers include airports, cruise ships, pharmacies and medical care facilities, and industrial and educational sites where a rapid result is required.

    Last week, XPhyto announced a strategically important acquisition for the future. With 3a-diagnostics GmbH, the Company acquired an essential piece of the puzzle for developing diagnostics for a purchase price of EUR 3.7 million. The two companies have been cooperating on a wide range of research topics since the beginning of last year. The focus is on the joint development and commercialization of cost-effective and easy-to-use biosensor screening tests and the associated development platforms for rapidly detecting infectious diseases. The Frickenhausen-based Company was also part of the research on the newly marketed 25-minute PCR test Covid-ID Lab.

    XPhyto stands on several pillars and is growing both organically and through targeted acquisitions. The market capitalization is EUR 78.6 million. Due to many projects, the Canadians are an exciting player in the diagnostics market in the long term.

    MorphoSys - Thumbs down

    Things are not looking good for the chart of the biotech Company MorphoSys. After breaking the critical support line at EUR 55, the share price plummeted with a loss of more than 6% to EUR 51.20, which represents a three-year low. The next stop would be the mark around EUR 50. Should this prominent support be torn, a slide to EUR 40 is quite likely.

    The reason for the sell-off was a dramatic reduction in sales targets for the full year 2021, after management already announced in the first quarter that sales could be halved due to very volatile production sales, and MorphoSys could once again post losses. Lower production sales of the cancer drug Monjuvi, which MorphoSys co-markets with Incyte in the US, is now forcing the Company to slash revenues. Sales are expected to reach EUR 155 million to EUR 180 million in 2021, down from previous estimates of up to EUR 200 million.

    Furthermore, costs grew more than expected in areas such as research and development and sales. In addition, the high expenses generated by the acquisition of Constellation Pharmaceuticals contributed to the weaker result. Operating expenses would now be EUR 435 million to EUR 465 million, down from a previous estimate of EUR 385 million. Our advice: Hands off!

    BioNTech - Good business

    At the moment, both the business and the share price of the German vaccine manufacturer BioNTech are developing much more positively. After a new all-time high, the share continues to run without signs of weakness, driven by the news. If you are invested, we recommend stopping under the gap opened last week at around USD 260 and letting the profits run.

    Further major orders came from the US last week. Because the government is preparing to vaccinate younger children and possibly necessary booster shots for adults, 200 million doses of BioNTech and Pfizer's Corona vaccine were ordered again, with half to be delivered by the end of the year. That brings the total number to be delivered to the US government by the two companies based on the existing supply agreement to 500 million doses of vaccine, according to BioNTech.

    The Coronavirus will be with us for a long time. As different variants form, more vaccines will be developed in the coming years, promising billions more in revenue. In addition to vaccine manufacturers such as BioNTech or Moderna, diagnostics producers or providers of rapid tests such as XPhyto will also profit.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by Nico Popp on September 27th, 2023 | 07:10 CEST

    Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Pharma

    High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!


    Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST

    Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets

    • Biotechnology
    • Pharma
    • Electromobility

    Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.


    Commented by André Will-Laudien on September 18th, 2023 | 06:30 CEST

    Unbelievable! Hands off AI, biotech in rebound! Bayer, Defence Therapeutics, Morphosys

    • AI
    • Biotechnology
    • Investments

    The big fall decline is now over. It is always a difficult time, but the so-called "Triple Witching" went relatively smoothly this time. The European Central Bank (ECB), in its first interest rate meeting after the summer break, decided to raise key rates by another quarter point to 4.00%, up from the previous 3.75% in July. At the same time, it lowered its inflation forecast for 2025 and the outlook for economic growth in the Eurozone for the years 2023 to 2025. Economic risks are increasing, but inflation remains the determining factor for interest rates. Expectations that the US Federal Reserve (FED) will announce an interest rate pause at its next meeting on Wednesday have boosted confidence. Last week's big losers were the recently favoured AI stocks Nvidia, Microsoft and However, the biotech sector has recently started to climb again. Where are the opportunities for investors?